Disclosure by Pfizer. In the interest of transparency relating to its relationships with investigators and study sites or to ensure compliance with applicable local law, Pfizer may publicly disclose the support it provides under this Agreement. Such a disclosure by Pfizer may identify both the Institution and the Principal Investigator, but will clearly differentiate between payments or other transfers of value to institutions and those made to individuals.
Disclosure by Pfizer. In the interest of transparency relating to its financial relationships with investigators and study sites or to ensure compliance with Applicable Law, industry codes and Pfizer policies, Pfizer may, and (in certain cases) is required to, report or otherwise disclose publicly payments or other transfer of value to certain health care providers, teaching hospitals and other health care organizations, including Funding provided under this Agreement. These laws and codes, and their implementing regulations, collectively are referred to as “Transparency Obligations.” Pfizer may disclose in any lawful manner the terms of this Agreement and any other information to the extent necessary for Pfizer to meet its Transparency Obligations. The terms of the Agreement shall be publicly disclosed on Pfizer’s webpage (xxx.xxxxxx.xx) when the Agreement is made and for a period of 2 years thereafter.
Disclosure by Pfizer. In the interest of transparency relating to its financial relationships with investigators and Study/Registry sites or to ensure compliance with Applicable Law, industry codes and Pfizer policies, Pfizer may, and (in certain cases) is required to, report or otherwise disclose publicly payments or other transfer of value to certain health care providers, teaching hospitals and other health care organizations, including Funding provided under this Agreement. These laws and codes, and their implementing regulations, collectively are referred to as “Transparency Obligations.” Pfizer may disclose in any lawful manner the terms of this Agreement poskytovaných státem. 3.5 Žádné platby účtované třetím osobám. Příjemce grantu zajistí, aby žádnému subjektu studie, pojišťovně, orgánu veřejné moci ani jinému plátci ze strany třetích osob nebyly účtovány žádné platby za jakékoli činnosti související se Studií/Registrem prováděné Příjemcem grantu za použití Financování. 3.6
Disclosure by Pfizer. Subcontractor acknowledges that Pfizer is subject to laws related to the collection and reporting of any payments or transfers of value to certain healthcare professionals and teaching hospitals (hereinafter: the “Payments to Healthcare Professionals”), including those laws, industry codes and accompanying implementing regulations, including section 6002 of the Affordable Care Act and The European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on Disclosure of Transfers of Value (hereinafter, collectively, the “Transparency Laws”). Pfizer may disclose in any lawful manner the terms of Master Agreement and SOW, the support that Pfizer is providing under it, and any other information to the extent necessary for Pfizer to meet its obligations under the Transparency Laws including certain identifying information of healthcare professionals including names, National Provider Identifier, licensure number(s), specialty, and addresses. Subcontractor will provide Penta and/or Pfizer with all information Pfizer needs to meet its obligations under any Transparency Laws including identifying healthcare professionals and teaching hospitals that receive a payment or transfer-of- value stemming from Pfizer’s support under the Master Agreement and SOW, as well as the amounts and dates of those payments or transfers-of-value. In accordance with EFPIA Disclosure Code and local country privacy and legal requirements, a signed consent document may be collected. Subcontractor will provide the information required under this paragraph by accurately completing a data report in a format reasonably determined by Pfizer.
Disclosure by Pfizer. In the interest of transparency relating to its relationships with investigators and study sites or to 2.2 Zverejnenie informácií zo strany spoločnosti Pfizer. V záujme transparentnosti ohľadom jej vzťahu so ensure compliance with applicable local law, Pfizer may publicly disclose the support it provides under this Agreement. Such a disclosure by Pfizer may identify both the Institution and the Principal Investigator, but will clearly differentiate between payments or other transfers of value to institutions and those made to individuals. skúšajúcimi a pracoviskami klinického skúšania, alebo aby sa zabezpečilo dodržiavanie príslušných právnych predpisov môže spoločnosť Pfizer zverejniť podporu, ktorú poskytuje v rámci tejto zmluvy. Takéto zverejnenie informácií zo strany spoločnosti Pfizer môže identifikovať inštitúciu aj hlavného skúšajúceho, ale jasne rozlíši medzi platbami alebo inými prevodmi hodnôt inštitúcii a jednotlivcom.
Disclosure by Pfizer. In the interest of transparency relating to its relationships with investigators and study sites or to ensure compliance with applicable local law, Pfizer may publicly disclose the support it provides under this Agreement. Such a disclosure by Pfizer may identify both the Health Services Provider and the Principal Investigator, but will clearly differentiate between payments or other transfers of value to legal persons and those made to individuals. Z veřejnění informací společností Pfizer. V zájmu transparence svých finančních vztahů se zkoušejícími a studijními pracovišti, nebo z důvodu zajištění dodržování příslušných místních právních předpisů, může společnost Pfizer zveřejnit finanční odměnu, kterou podle této Smlouvy poskytuje. Takové zveřejnění společností Pfizer může identifikovat jak Poskytovatele zdravotních služeb, tak i Hlavního zkoušejícího, ale bude zřetelně rozlišovat mezi platbami a jinými převody hodnot, jež jsou poukázány právnickým osobám, a těmi, jež jsou poukázány jednotlivcům.
Disclosure by Pfizer. In the interest of transparency relating to its relationships with 2.2
